TMPRSS6-Targeting dsRNA Composition for Iron Overload Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with elevated iron levels, such as hemochromatosis and thalassemia, are inadequate in effectively reducing iron overload, as they do not target the underlying mechanism of TMPRSS6 gene expression.
Innovation Solution
The use of double-stranded RNA (dsRNA) molecules, known as iRNAs, that specifically target and inhibit or activate the TMPRSS6 gene expression through RNA-induced silencing complex (RISC) pathways, leading to modulation of iron homeostasis by reducing or increasing TMPRSS6 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current treatments for iron overload conditions are used, then iron levels are reduced to some extent, but the reduction is inadequate and does not effectively address iron overload
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (TMPRSS6 gene expression) that regulates iron homeostasis. By using iRNAs to specifically bind and inhibit TMPRSS6 mRNA, the treatment extracts the pathological element (dysregulated TMPRSS6 expression) from the system, thereby effectively reducing iron overload that conventional treatments failed to address adequately
Solution Approach 2:
The patent introduces iRNAs as intermediary molecules that mediate between the treatment agent and the target gene expression. These iRNAs serve as intermediaries that specifically bind to TMPRSS6 mRNA and recruit RNA-induced silencing complexes, thereby translating the therapeutic intent into precise gene expression inhibition and effective iron level reduction
2Quantity of substance
If conventional treatments are applied, then some iron reduction occurs, but the underlying mechanism of TMPRSS6 gene expression is not targeted
Solution Approach 1:
The patent extracts the specific molecular target (TMPRSS6 gene expression mechanism) from the complex physiological system. By designing iRNAs with sequences complementary to TMPRSS6 mRNA, the treatment specifically extracts and inhibits this underlying mechanism, providing adaptability to target the root cause rather than just symptoms
Solution Approach 2:
The patent applies local quality by making the treatment highly specific to TMPRSS6 gene expression through complementary base pairing between iRNA and target mRNA. This localized specificity ensures that only the relevant molecular mechanism is inhibited, while other physiological processes remain unaffected, thereby achieving mechanism-targeted therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The iRNAs effectively decrease iron levels by inhibiting TMPRSS6 expression, thereby alleviating symptoms of iron overload disorders like hemochromatosis and thalassemia, with significant reductions in serum iron, ferritin, and transferrin saturation levels.
Implementation Method 1
the iRNA mediates the RNA-induced silencing complex (RISC) pathway to effect the cleavage of an RNA transcript
Data Source
AI summary
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.